...
首页> 外文期刊>Journal of biomedical nanotechnology >Combination of Anti-Diabetic Drug Metformin and Boswellic Acid Nanoparticles: A Novel Strategy for Pancreatic Cancer Therapy
【24h】

Combination of Anti-Diabetic Drug Metformin and Boswellic Acid Nanoparticles: A Novel Strategy for Pancreatic Cancer Therapy

机译:抗糖尿病药物二甲双胍和乳香酸纳米粒子的组合:一种胰腺癌治疗的新策略。

获取原文
获取原文并翻译 | 示例
           

摘要

Pancreatic cancer has an infaust prognosis and is the fourth common cause of cancer related death in India. It is highly resistant to conventional treatment modalities such as chemotherapy, radiation therapy and surgery. The association of pancreatic cancer and diabetes mellitus is explored in our study. Pancreatic cancer is more likely to occur in people who have diabetes than people devoid of it, which is supported by the observation that hyperglycaemia occurs at an early stage of pancreatic cancer and is indeed a risk factor. In the present study, we have demonstrated a synergistic relationship between metformin and boswellic acid nanoparticles with varying doses of boswellic acid nanoparticles and constant metformin (20 mM). The effect revealed increased synergism between metformin and boswellic acid nanoparticles through the inhibition of cell proliferation with an effect of 80% for the combination with 0.3 mg/mL and 0.4 mg/mL and a constant concentration of metformin. We examined the effect of combination on cell migration which revealed time dependent inhibitory effect on pancreatic cell line (MiaPaCa-2). Also, we found that the combinatorial approach significantly decreased colony formation and exhibited high rate of induction of apoptosis through DNA fragmentation in pancreatic cancer cells. In-vitro hemolysis confirmed the hemocompatibility of the combination therapy with metformin and boswellic acid nanoparticles. Flow cytometry based apoptosis assay and Caspase mediated apoptosis proved apoptosis mediated cell death. Further, the cells were analysed with mitochondrial membrane potential kit which revealed depolarization of mitochondrial membrane potential due to apoptosis after treatment with drug combination. Hence, the combination approach proved to be a promising therapy towards pancreatic cancer.
机译:胰腺癌的预后很差,是印度癌症相关死亡的第四大常见原因。它对常规疗法如化学疗法,放射疗法和外科手术具有很高的抵抗力。在我们的研究中探讨了胰腺癌和糖尿病的关系。患有糖尿病的人比没有糖尿病的人更容易发生胰腺癌,这是因为高血糖症发生在胰腺癌的早期,并且确实是危险因素,这一观察结果支持了这一观点。在本研究中,我们已经证明了二甲双胍与乳香酸纳米颗粒之间存在协同作用,并且具有不同剂量的乳香酸纳米颗粒和恒定的二甲双胍(20 mM)。该作用表明,通过抑制细胞增殖,二甲双胍与乳香酸纳米颗粒之间的协同作用增强,与0.3 mg / mL和0.4 mg / mL的组合以及恒定浓度的二甲双胍联合使用,效果达到80%。我们检查了组合对细胞迁移的影响,揭示了对胰腺细胞系(MiaPaCa-2)的时间依赖性抑制作用。此外,我们发现组合方法显着降低了集落形成,并通过胰腺癌细胞中的DNA片段化表现出高诱导凋亡率。体外溶血证实了二甲双胍和乳香酸纳米颗粒联合治疗的血液相容性。基于流式细胞术的细胞凋亡检测和Caspase介导的细胞凋亡证明了细胞凋亡介导的细胞死亡。此外,用线粒体膜电位试剂盒分析细胞,该试剂盒揭示了用药物组合治疗后由于凋亡引起的线粒体膜电位去极化。因此,组合方法被证明是针对胰腺癌的有前途的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号